Mella finds hypometabolic state in ME/CFS

Health rising blog post, by Cort Johnson, 15 October 2016: Another Hypometabolic Signature Found

Fluge and Mella are best known for their Rituximab work, but just last week Mella reported that they’d found a hypometabolic state in ME/CFS as well. Check out that with along with what’s going on with Rituximab, and another chemotherapy autoimmune drug that may help some patients

olav_mella-pngProf Olav Mella

Naviaux’s paper has clearly sparked a lot of interest. Certainly, antecedents hovered in the background; metabolism has actually been a niche topic in ME/CFS for years. Lemle proposed a hydrogen sulfide induced state of hibernation or hypometabolism caused the low energy problems in chronic fatigue syndrome in 2011. The Aussies have been doing metabolomics research for quite some time. Their 2014 review paper argued it could be helpful in ME/CFS.

Metabolomics is not a niche topic anymore. The Japanese, who have also done metabolomics research, recently released a metabolomics ME/CFS study (to be covered soon).

Last month Hanson reported finding evidence of a hypometabolic state in ME/CFS, and now Fluge and Mella have apparently found it as well. The metabolites they’ve found suggest to them that low energy production is a central feature of this disease.

Problems producing energy appear to be fundamental and extend to the immune cells – something Ron Davis has proposed. Fluge and Mella reportedly found reduced levels of phosphate – the P in ATP – in immune cells in ME/CFS. That suggests the reduced killing ability of NK and T-cells could be caused by poor energy production. That makes sense given that some immune cells need to power up to kill pathogens.

Fluge and Mella also have evidence suggesting that metabolic problems may be loading ME/CFS patients with lactic acid – a by-product of anaerobic energy production. (If aerobic energy production is impaired or insufficient, the less-efficient, dirtier and lactic-acid producing anaerobic energy production process kicks in.)

These Norwegian researchers believe ME/CFS patients have two problems with lactic acid; they’re producing too much of it, and are having trouble getting rid of it. Mella noted that he produces lactic acid but he can get rid of it quickly – people with ME/CFS cannot. Lactic acid remains a puzzling subject – some researchers find it increased and others do not. That variability may reflect a subset issue.

Rituximab Update

If my calculations are correct, the trial is a bit over halfway done, and we should expect it to end sometime in the summer of next year. At that point, Fluge and Mella will crack the code, and by late 2017 (optimistically) or the first half of 2018, we should know the results.

We’ve seen some promising Phase III trials go bust recently. Because the larger Phase III trials include more types of patients, they often have less positive results, and Mella warned that this was possible in Rituximab as well. If the results don’t apply to ME/CFS overall, then the goal will be to find out which patients it’s effective in and target them. Mella noted that different mechanisms can produce the same symptoms in autoimmune diseases, and he expects this is true in ME/CFS.

According to the translation, Mella stated that they can be “reasonably sure” that a subset of the patients responded. Whether enough people respond to make the trial statistically significant is another matter. Rituximab could be effective in some patients, but not in enough to result in a significant overall response.

(Dr. Patrick in Canada believes he may have found a biomarker that will help identify which patients respond to Rituximab. Dr. Peterson is reportedly testing that biomarker in his patients. )

Mella also cautioned that even if the Norwegian trial is successful, each country will have to put on its own trial. (As it is now, Rituximab would be available off-label to doctors willing to prescribe it, but the drug is very expensive.) The U.S. – the most difficult place to get drug approval – will need its own trial.

According to clinicaltrials.gov. the NIH, one of the biggest clinical trial producers in the world, is currently recruiting for no less than 49 Rituximab trials, mostly in cancer but also in lupus and other autoimmune disorders.

How the NIH, after the IOM and P2P reports, and its statements that ME/CFS constitutes a serious, unmet need, could find a way to not to fund a Rituximab trial in the face of a successful Norwegian trial is unclear, but if any group can find a way, surely the NIH can. If the NIH waits for the results of Fluge/Mella’s trial before proceeding, we might be looking at a U.S. Rituximab trial beginning in 2019 with the results in 2020 or 2021…..

It’s remarkable to continue to see the NIH with its 30 plus billion budget continue to sit on its hands while a small country like Norway produces a large Rituximab trial.

Another Drug Possibility…..Cyclophosphamide

Chemotherapy may end up being very good to chronic fatigue syndrome. Fluge and Mella have been giving twenty-five people who didn’t respond to Rituximab or who relapsed after getting it, a shot at another chemotherapeutic drug called cyclophosphamide. Cyclophosphamide is used to treat cancer, autoimmune diseases, and amyloidosis.

A quite toxic drug, Wikipedia reports that it’s side effects usually limit it to the beginning phases of treatment in autoimmune diseases. It’s typically used only when first-line treatments such as Rituximab don’t work. Like Rituximab it’s an immune suppressant.

Not all immune suppressants are the same; etanercept (Enbrel) didn’t work for Mella and Fluge. Cyclophosphamide findings have, interestingly, excited some hospitals…

Fluge and Mella are using cyclophosphamide in the lower doses associated with autoimmune diseases. They reported that while some people get worse at first, it does appear to work in some ME/CFS patients. Like in autoimmune diseases, the positive effects show up months after taking the drug. Approval for a second trial with severely ill ME/CFS patients has been received.

“Toxic Blood?” (or Another Good Reason Not to Donate Blood)

The idea that something in ME/CFS patient’s blood may be turning off the mitochondria or natural killer cells or what have you is not a new one. Although no new studies have come out, reports indicate that the natural killer cell problems in ME/CFS apparently disappear when NK cells from ME/CFS patients are put into a healthy person’s blood. Conversely, healthy NK cells poop out when put into ME/CFS patient’s blood. Fluge and Mella are finding that healthy muscle cells act strangely when cultured with ME/CFS patient’s blood.

Fluge and Mella are also finding that the blood vessels of ME/CFS patients are producing too little nitric oxide. Nitric oxide is a gas produced in the walls of the blood vessels which allows them to enlarge and increase blood flow. If you produce too little nitric oxide, your blood vessels will be so constricted that getting enough blood to the muscles during exercise or other blood requiring activities will be impossible.

Nitroglycerin tests indicate that ME/CFS patient’s ability to produce nitric oxide is still present, suggesting presumably that either the signal to produce NO is not being sent or is being ignored, or that the cells that produce NO are being shut down in some way.

Fluge and Mella filed a patent in 2014 to use a nitric oxide donor in conjunction with Rituximab in ME/CFS. Their understanding of the role that blood flows play may date back from her. After checking into a hospital for chest pains she found that a nitric oxide donor (Imdur) improved her symptoms in much the same way as Rituximab had – except that the results were immediate. They got moderate results in six patients and suggested that using supplements with relatively high doses of L-Arginine 5 g twice daily combined with L-Citrulline 200 mg twice daily might suffice as well.

See Fluge/Mella Take out Patent on Nitric Oxide Treatment for ME/CFS

Finding some factor in the blood that turns things off could be very helpful. It could a) directly point to a cause, and b) to clear treatment options that block the factor or stop it from being produced.

Fluge and Mella’s Journey

Fluge and Mella’s range has become so large, that it’s totally inappropriate at this point to think of them as Rituximab researchers; they’re after the source of ME/CFS itself. They’re looking at the immune system, blood flows, exercise metabolism, and genetics and have developed a model which incorporates all of it.

They’ve experimented with at least three different drugs. They’ll be presenting the data from the Rituximab trial in an open source format so that it’s available to other researchers. A 150-person Biobank that is storing blood taken before and after ME/CFS patients receive Rituximab could reap dividends. We’re lucky to be the focus of two such creative and persistent researchers.

Other researchers – most of whom I would guess were not interested in ME/CFS prior to their work – have clearly been excited by it. Their international partners draw from the Charite University Hospital in Berlin, UCL London, Arizona State University and Institute of Immunology Rikshospitalet and Biomedisn UiB.

Fluge and Mella are going to make their first trip, so far as I can tell, to the U.S. for the IACFS/ME conference where Dr. Fluge’s plenary address will focus on how the Rituximab trials have helped him and Mella understand the cause of ME/CFS. At the Patient Day we’ll get a trifecta; Fluge, Mella and Dr. Peterson on “Rituximab and Emerging Treatments”. It’s a rich time for them and for us.

This blog is based on a post on Phoenix Rising describing Dr. Mella’s Oct. 10th talk in Arendal, Norway and a typically tortured Google translation of part of that talk.

Posted in News | Tagged , , , , , , , , , | Comments Off on Mella finds hypometabolic state in ME/CFS

Tired all the time? Why fatigue isn’t just about sleep

New Scientist article, by Emma Young, 12 October 2016:  Tired all the time? Why fatigue isn’t just about sleep

Some of us feel constantly drained without knowing why. Some answers are emerging at last, and it’s not down to lack of sleep

You’re in bed by 11, having had a busy, productive day. After a full night’s sleep you wake up naturally and feel… exhausted.

If this sounds familiar, you’re not alone. According to a recent survey of over 20,000 people by researchers at Radboud University in the Netherlands, about 30 per cent of visits to doctors involve complaints about being tired all the time. Some 20 per cent of people in the US report having experienced fatigue intense enough to interfere with living a normal life. This hits us in our pockets, too: workers who are unproductive because of fatigue cost US employers more than $100 billion a year.

It’s perhaps surprising, then, that we are only now beginning to work out what fatigue actually is. Until recently, daytime tiredness was presumed to be nothing more mysterious than simple physical exhaustion or feeling the need to sleep – the US Centers for Disease Control and Prevention estimates that 35 per cent of people are short on sleep. Combine that with the fact that tiredness is subjective and therefore difficult to measure, plus the subject falls somewhere between studies of the body and mind, and it’s small wonder fatigue has largely escaped scientific scrutiny.

Since tiredness accompanies so many common diseases, not to mention ordinary ageing, a better understanding of its causes could improve quality of life for pretty much everybody. A handful of researchers are now trying to figure out the causes, and possible fixes. Although it’s early days, a few clues are emerging.

One cause, we might think, is that life is more exhausting than it has ever been. Caught between the competing demands of work and family, not to mention the ever-present buzz of smartphone notifications, it is no surprise so many of us feel as if we are running on empty. Yet this may be a fallacy. According to Anna Katharina Schaffner, a historian at the University of Kent in Canterbury, UK, and author of Exhaustion: A history, people through the ages have consistently complained of being worn out, and harked back to the relative calm of simpler times. Over the centuries, fatigue has been blamed on the alignment of the planets, a lack of godliness and even an unconscious desire to die, says Schaffner. “Freud argued that a very strong part of ourselves longs for a state of permanent physical and mental rest,” she says.

In the 19th century, a new diagnosis appeared: neurasthenia. The American physician George M. Beard claimed that this condition, supposedly caused by exhaustion of the nervous system, was responsible for physical and mental fatigue as well as irritability, hopelessness, bad teeth, cold feet and dry hair. Beard blamed neurasthenia on the advent of steam power and newfangled inventions such as the telegraph. Women’s education was also considered to be tiring for all concerned, while the advent of the printing press brought an abundance of newspapers and magazines to keep up with.”Beard feared that the modern subject was unable to cope with such chronic sensory overload,” says Schaffner.

If modern life isn’t to blame, another possibility is that at least some fatigue is down to a lack of sleep. Researchers distinguish between the need for sleep and fatigue, however, considering them to be closely related but subtly different. The good news is that there is a fairly easy way to tell which might be wearing us out: the sleep latency test. Used widely in sleep clinics, it is based on the idea that if you lie down somewhere quiet during the day and fall asleep within a few minutes, then you are either lacking sleep or potentially suffering from a sleep disorder. If you don’t drop off within 15 minutes or so, yet still feel tired, fatigue might be the problem.

So if it’s not the same thing as sleepiness, what is fatigue? Mary Harrington, a neuroscientist at Smith College in Northampton, Massachusetts, is one of a handful of researchers looking for a telltale biological signal of fatigue. So far no single marker has emerged that tallies with how tired people say they feel, but “we do have some candidates”, she says.

Circadian clock problems

One possibility Harrington is investigating is that daytime fatigue stems from a problem with the circadian clock, which regulates periods of mental alertness through the day and night. This regulation falls to the brain’s suprachiasmatic nucleus, which coordinates hormones and brain activity to ensure that we feel generally alert by day. Under normal circumstances, the SCN orchestrates a peak in alertness at the start of the day, a dip in the early afternoon, and a shift to sleepiness in the evening.

The amount of sleep you get at night has little impact on this cycle, says Harrington. Instead, how alert you feel depends on the quality of the hormonal and electrical output signals from the SCN. The SCN sets its clock by the amount of light hitting the retina, so that it keeps in line with the solar day. Too little light in the mornings, or too much at night, can disrupt SCN signals, and either can lead to a lethargic day. “I think circadian rhythm disruption is quite common in our society and is getting worse with increased use of light at night,” says Harrington.

If you spend the day feeling as if you have never quite woken up properly but are not sleepy at bedtime, a poorly calibrated SCN might be to blame, says Harrington. She suggests trying to spend at least 20 minutes outside every morning and turning off screens by 10 pm to avoid tricking the SCN into staying in daytime mode.

Another way to reset the SCN is to exercise, Harrington suggests. Several studies have linked exercise – whether a single bout or regular physical exertion – to reduced fatigue. “People with fatigue hate to hear this, but exercise can make a big difference,” she says. This may explain why people who start exercising regularly often report sleeping better, when some studies show they don’t actually sleep for any longer. Quality of sleep may be more important than quantity.

Body fat & hormones

As well as resetting the SCN, exercise fights the flab, and there are good reasons to think that reducing fat levels could help tackle fatigue. Body fat not only takes more energy to carry around, but releases leptin, a hormone that signals to the brain that the body has adequate energy stores. Studies have linked higher leptin levels to greater perceived fatigue, a finding that makes perfect sense from an evolutionary perspective: if you aren’t short of food, you don’t need the motivation to go out and find some. Interestingly, people who fast regularly often report feeling more energetic than when they ate frequently.

With obesity on the rise, leptin signalling might well be a common reason for feeling tired all the time. But there could be something else at play. People who carry excess fat also show higher levels of inflammation, a part of the body’s immune response that rouses other parts into action by releasing proteins called cytokines into the bloodstream. Body fat stores large quantities of cytokines, which may mean that more end up circulating, too. As well as stimulating the immune system, cytokines also make you feel drained of energy, as anyone who has ever had a common cold can attest. In 1998, Benjamin Hart at the University of California, Davis, argued that this feeling is an evolved strategy to help fight a bacterial or viral attack: when you need time to rest and recuperate, fatigue is your friend.

Animal studies have shown this effect in action. In one, Harrington gave mice a drug that causes low-level inflammation. She found that while they still moved around their cages and ate as normal, they avoided the running wheels. Contrast that with healthy mice, which seem to seek out the wheels for kicks. “It is like wanting to go out and be active, and have fun and do something that is not necessary for just staying alive.” If low-grade inflammation robs mice of their zest for life, there’s no reason, she thinks, to suspect something similar shouldn’t hold for people.

Robert Dantzer at the University of Texas M. D. Anderson Cancer Center, Houston, and colleagues have found changes in a few key brain areas that might account for a lack of motivation. They describe how inflammation alters activity in motivation-linked brain areas such as the fronto-striatal networks involved in reward-based decision-making, and the insula, which processes the bodily sensation of fatigue. These changes could explain aspects of fatigue such as a lack of motivation, uncertainty about what to do, and simply being aware of feeling sapped.

Chronic, lower-level inflammation

Even if you’re not overweight or sick, inflammation could still be running you down. A sedentary lifestyle, regular stress and poor diet – one high in sugar and low in fruits and vegetables – have all been linked to chronic, lower-level inflammation. There is also preliminary evidence that disruption of circadian rhythms can increase inflammation in the brain. So could lifestyle-related inflammation help to explain why so many of us feel so tired so much of the time? “The answer is yes,” says Dantzer. Epidemiological surveys do point to a relationship between fatigue and elevated levels of IL-6, an inflammatory marker, he says.

It’s early days, but inflammation is emerging as potentially a common pathway linking fatigue to everything from poor-quality sleep and physical inactivity to a bad diet. If that’s correct, then a handful of potential lifestyle changes could go a long way to fighting everyday fatigue: more exercise, and eating more fruits and vegetables that contain high levels of polyphenols (such as resveratrol in grapes or curcumin in turmeric), which some studies suggest can reduce inflammation.

Inflammation probably isn’t the whole answer, though, says Anna Kuppuswamy, a neuroscientist at the Institute of Neurology at University College London. Kuppuswamy studies people who suffer debilitating fatigue in the aftermath of a stroke, a time when their brains are highly inflamed. “Inflammation is definitely a trigger for fatigue. But what is frustrating is that we find fatigue in people long after inflammatory markers normalise,” she says.

The role of dopamine

Another factor muddying the waters is that biological signals that might lead to a feeling of overwhelming exhaustion in one person won’t necessarily trigger it in another. Some people are able to push through it, says Kuppuswamy.

That requires motivation, low levels of which are clearly an important aspect of fatigue. So some researchers have been looking at the role of dopamine – a neurotransmitter that drives us to seek out pleasure. When dopamine is lost, as happens in Parkinson’s disease, for example, the accompanying depression and apathy that comes with it can be crushing.

Low dopamine is also implicated in depression, as is reduced availability of another neurotransmitter, serotonin. Since the vast majority of people with major depression report severe fatigue, and about one in five people become depressed at some point in their lives, it’s no wonder that depression is also a potential common factor in fatigue.

Depression

Ranjana Mehta, director of the NeuroErgonomics Lab at the Texas A&M Institute for Neuroscience, is one researcher who points to widespread depression as an explanation for why so many of us feel so drained. As her team has recently shown, the kind of mental exhaustion that accompanies depression can lead to a real sense of physical fatigue. In experiments, people who were asked to lift weights while doing mental arithmetic had 25 per cent less endurance than those who simply lifted weights. Subsequent imaging studies showed why: thinking hard lowers activity in frontal brain regions, which are involved in directing movements as well as having a hand in concentration. When the brain is challenged, it can make muscles tired, too.

With so many emerging causes for fatigue, interest in trying to crack the problem is growing. The US National Institutes of Health is in the planning stages of a programme aimed at finding the elusive physical signatures of fatigue. Harrington says that better animal models are needed, along with a concerted effort from many more researchers to rescue fatigue once and for all from medical obscurity. “I’ve done a lot of work on this because I think we can crack it,” she says. “But I do feel pretty alone out there.”

In the meantime, Harrington’s advice is not to let fatigue stop you doing something you enjoy. In fact, it is worth forcing yourself to keep at it because a potent reward could trigger the release of dopamine in brain areas linked to motivation and alertness. Alternatively, do something stressful: the release of adrenaline could help you overcome lethargy. Ideally, put stress and enjoyment together. As Harrington says, “who feels fatigued when they’re on a roller coaster?”

Missing something?

Pharmacy shelves are groaning with supplements claimed to “fight fatigue” and help you “re-energise”. So is there any evidence that boosting some magic ingredient will endow us with greater vitality?

Iron
Too little iron certainly can lead to fatigue. And while only 3 per cent of men and 8 per cent of women are diagnosed with clinical iron-deficient anaemia, there is some evidence that iron supplements may still provide an energy boost for the rest. One group of non-anaemic women who experienced “considerable fatigue” had their fatigue score nearly halve after 12 weeks on iron tablets. Those on a placebo reported a 29 per cent drop, however, so the true effect is hard to gauge. Nevertheless, we need to understand the importance of iron deficiency in fatigue – even where there is no anaemia, according to Jill Waalen, an epidemiologist at the Scripps Research Institute in La Jolla, California.

B vitamins
B vitamins are also commonly touted as a magic bullet to boost energy, but there is little evidence that supplements will make any difference unless you are deficient. David Kennedy, who researches the impacts of nutrients on brain function at Northumbria University in Newcastle Upon Tyne, UK, says that while most people who eat a healthy diet shouldn’t expect any benefit from the standard B6, B9 or B12 supplements, we don’t fully understand how all eight B vitamins interact in the body, and that people who are obese or eat a poor diet could well be deficient in at least one of them. So, he suggests, there may be an argument for taking B-vitamin supplements, but only if you take them all rather than a select few.

Flavonols
There is some evidence that flavonols, found in dark chocolate, wine and tea, can mildly enhance blood flow to the brain, says Kennedy. So consuming them may boost brain functioning and alertness, although he points out that exercise is more effective than supplements at boosting brain blood flow.

Water
Dehydration is often cited online as an explanation of why so many of us feel tired. There is some evidence to support the idea. One study at the University of Connecticut, for example, found that “mild dehydration” – a 1.5 per cent dip below the body’s normal water volume, which the team says can occur in the course of routine activities – can cause fatigue and difficulty concentrating, particularly in younger women. On the other hand, a 2 per cent drop in hydration is enough to make us feel thirsty, so if we drink normally we shouldn’t get dehydrated very often and it probably isn’t necessary to force down gallons of the stuff.

Hormones
Also much trotted out in cyberspace is the notion that long-term stress drains the adrenal glands, leading to tiredness and weakness. Adrenal fatigue is not a diagnosis recognised by the medical establishment – it was James Wilson, a chiropractor and naturopath, who came up with it in 1998. “No scientific proof exists to support adrenal fatigue as a true medical condition,” says Katherine Chubinskaya, an endocrinologist in Vancouver, Canada. Adrenal insufficiency, however, a condition in which the adrenal cortex does not produce enough hormones – is real enough but also rare, so is unlikely to be the cause of most common fatigue.

Emma Young is a science writer based in Sheffield, UK

Posted in News | Tagged , , , , , , | Comments Off on Tired all the time? Why fatigue isn’t just about sleep

Review of treatment for depression in paediatric CFS or ME

Review abstract:

Objectives: At least 30% of young people with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) also have symptoms of depression.

This systematic review aimed to establish which treatment approaches for depression are effective and whether comorbid depression mediates outcome.

Setting: A systematic review was undertaken. The search terms were entered into MEDLINE, EMBASE, PsycInfo and the Cochrane library.

Participants: Inclusion and exclusion criteria were applied to identify relevant papers. Inclusion criteria were children age <18, with CFS/ME, defined using CDC, NICE or Oxford criteria, and having completed a valid assessment for depression.

Results: 9 studies were identified which met the inclusion criteria, but none specifically tested treatments for paediatric CFS/ME with depression and none stratified outcome for those who were depressed compared with those who were not depressed. There is no consistent treatment approach for children with CFS/ME and comorbid depression, although cognitive-behavioural therapy for CFS/ME and a multicomponent inpatient programme for CFS/ME have shown some promise in reducing depressive symptoms. An antiviral medication in a small scale, retrospective, uncontrolled study suggested possible benefit.

Conclusions: It is not possible to determine what treatment approaches are effective for depression in paediatric CFS/ME, nor to determine the impact of depression on the outcome of CFS/ME treatment. Young people with significant depression tend to have been excluded from previous treatment studies.

Treatment for paediatric chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) and comorbid depression: a systematic review, by Maria E Loades, Elizabeth A Sheils, Esther Crawley in BMJ Open Vol. 6, 11 October 2016

Posted in News | Tagged , , , , , , | Comments Off on Review of treatment for depression in paediatric CFS or ME

Increased risk of mortality in patients with ME & CFS

Research abstract:

Background:
There is a dearth of research examining mortality in individuals with myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS). Some studies suggest there is an elevated risk of suicide and earlier mortality compared to national norms. However, findings are inconsistent.

Objective:
This study sought to determine if patients are reportedly dying earlier than the overall population from the same cause.

Methods:
Family, friends, and caregivers of deceased patients were recruited. This study analyzed data including cause and age of death for 56 individuals.

Results:
The findings suggest patients in this sample are at a significantly increased risk of earlier all-cause (M = 55.9 years) and cardiovascular-related (M = 58.8 years) mortality, and they had a  directionally lower age of death for suicide (M = 41.3 years) and cancer (M = 66.3 years) compared to the overall U.S. population [M = 73.5 (all-cause), 77.7 (cardiovascular), 47.4 (suicide), and 71.1 (cancer) years of age].

Conclusions:
Results suggest there is an increase in risk for earlier mortality in patients. Due to sample size and over-representation of severely ill patients, the findings should be replicated to determine if the directional differences for suicide and cancer mortality are significantly different from the overall population.

Extract: As stated, several factors may contribute to an individual with ME or CFS having suicidal thoughts or actions and the development of depression-like symptoms including: lack of treatment options and low recovery rates [59–61]; increased levels of pain and disability [33,41]; greatly diminished QOL [39,41,54]; stigma and the beliefs sometimes held by family, friends, and even physicians that the illness is not real or is just depression [62– 65]; job loss and subsequent poverty [66,67]; and social and familial isolation [68,69].

McInnis et al. [70] found that patients with ME and CFS experience unsupportive social interactions significantly more often than healthy individuals or patients with more legitimized autoimmune illnesses (i.e. rheumatoid arthritis, lupus erythematosus, and multiple sclerosis) so they are experiencing people telling them that they are overreacting or are emotionally and physically abandoning the patient.

Mortality in patients with myalgic encephalomyelitis and chronic fatigue syndrome, by  Stephanie L. McManimen, Andrew R. Devendorf, Abigail A. Brown, Billie C. Moore, James H. Moore & Leonard A. Jason in Fatigue: Biomedicine, Health & Behavior [Published online: October 12, 2016]

Full text

Posted in News | Tagged , , , , , , | Comments Off on Increased risk of mortality in patients with ME & CFS

Possible clinical diagnostic tool for CFS based on the ratios of metabolites in blood plasma

Research abstract:

Chronic fatigue syndrome (CFS) is a persistent and unexplained pathological state characterized by exertional and severely debilitating fatigue, with/without infectious or neuropsychiatric symptoms, lasting at least 6 consecutive months. Its pathogenesis remains incompletely understood.

Here, we performed comprehensive metabolomic analyses of 133 plasma samples obtained from CFS patients and healthy controls to establish an objective diagnosis of CFS. CFS patients exhibited significant differences in intermediate metabolite concentrations in the tricarboxylic acid (TCA) and urea cycles.

The combination of ornithine/citrulline and pyruvate/isocitrate ratios discriminated CFS patients from healthy controls, yielding area under the receiver operating characteristic curve values of 0.801 (95% confidential interval [CI]: 0.711–0.890, P < 0.0001) and 0.750 (95% CI: 0.584–0.916, P = 0.0069) for training (n = 93) and validation (n = 40) datasets, respectively. These findings provide compelling evidence that a clinical diagnostic tool could be developed for CFS based on the ratios of metabolites in plasma.

Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles, by Emi Yamano, Masahiro Sugimoto, Akiyoshi Hirayama, Satoshi Kume , Masanori Yamato, Guanghua Jin, Seiki Tajima, Nobuhito Goda, Kazuhiro Iwai, Sanae Fukuda, Kouzi Yamaguti, Hirohiko Kuratsune, Tomoyoshi Soga, Yasuyoshi Watanabe & Yosky Kataoka in
Scientific Reports 6, Article number: 34990 (2016) [Published online: 11 October 2016]

 

Posted in News | Tagged , , , , , | Comments Off on Possible clinical diagnostic tool for CFS based on the ratios of metabolites in blood plasma

GMC removes restrictions from Dr Nigel Speight

Six months after WAMES medical advisor Dr Nigel Speight was told to cease all ME related activity, the GMC has lifted all restrictions.

P1020748aME Association blog post, 12 October 2016: Dr Nigel Speight – some excellent news from the General Medical Council
We are delighted to be able to report some very good news about Dr Nigel Speight.

Dr Speight has just been before a review panel at the MPTS (Medical Practitioners Tribunal Service).

The panel decided to overturn all of the restrictions that were imposed on him last April by the General Medical Council (GMC).

These restrictions were to the effect that Dr Speight was not allowed to see any cases of ME, or to give any advice, or to have anything to do with the subject. This was provisionally to be for a period of 15 months.

The barrister representing Dr Speight at the tribunal stated that the whole issue revolved around a single complex case, and involved an area of medical controversy on which the GMC should not take sides. She stated that there was no evidence of patient harm, indeed the evidence was to the contrary, and that the patient had improved considerably since Dr Speight’s intervention.

The barrister also emphasised how these GMC restrictions had led to the ME community being ‘deprived of choice’. The charities he supports (including the MEA) had not been able to find a replacement for him and so there is no one to support families in contentious cases involving children and adolescents, as no other doctor wishes to ‘put their head above the parapet’.

The panel then decided to remove the restrictions in their entirety and without qualification.

Once the GMC has confirmed the situation, Dr Speight will be able to return to his position as Honorary Paediatric Medical Adviser at the MEA

Nigel Speight commented:

“As you can imagine this comes as a great relief.

Needless to say, I am exceedingly grateful to all who wrote in to the GMC in my support, and it was mainly because of them that I chose to contest this issue.

Best wishes and thanks to you all

Nigel Speight”

Posted in News | Tagged , , | Comments Off on GMC removes restrictions from Dr Nigel Speight

The art & science of ME/CFS: a 2016 synopsis by Dr Daniel L. Peterson

Article abstract:

ME/CFS, a complex multisystem disease of diverse etiology, which results in significant functional and costly impairment, is estimated to affect approximately 40,000 Swedish residents.

This synopsis describes developments by governmental agencies (i.e. the CDC); emerging clinical centers in Stockholm and Gothenburg, and the sophisticated Swedish research addressing basic and translational medicine, and physician education.

A model is presented for Centers of Excellence, additional issues addressed: name change controversy, subsetting of patients, Big Data and Precision medicine, the microbiome, and current treatment challenges.

Research obstacles and solutions are outlined including the profound lack of funding and attention afforded by government agencies, academic institutions, and pharmaceutical industry. Development of C.O.E.’s and optimism; based on new science and technology with worldwide collaboration, suggest hope for the future.

The art and science of ME/CFS: a 2016 synopsis, by Dr Daniel L. Peterson in Socialmedicinsk tidskrift Vol 96 no. 4 2016

Download full article

Dr Daniel Peterson is a scientific advisor for Simmaron Research

peterson

Posted in News | Tagged , , , | Comments Off on The art & science of ME/CFS: a 2016 synopsis by Dr Daniel L. Peterson

A race to produce the first drug for CFS? Dr Jarred Younger talks

Health rising blog post, by Cort Johnson, 5 October 2016: A Race To Produce the First Drug for Chronic Fatigue Syndrome? Jarred Younger Talks

the-drug

Drug companies interested in ME/CFS? A race to produce the first drug for ME/CFS? A race? Those almost sound like fantasies but that’s the message Jarred Younger brought in his recent video talk.

Are drug companies finally getting interested in ME/CFS?
The bottom line, he said, is that over the last three months he’s met with pharmaceutical companies who’ve realized that the first company to bring an ME/CFS drug to market is going to hit it big. Younger didn’t mention it, but it’s hard to believe that Ampligen’s approval in Argentina hasn’t caused the pharmaceutical industry to wake up a bit.

(One only has to look at Lyrica’s success in fibromyalgia. Lyrica is clearly not a perfect drug; it’s side effects prevent many from using it, but that hasn’t stopped it from becoming a blockbuster drug. In 2014 Lyrica, which is also approved for other conditions, was Pfizer’s top-selling drug and the top selling central nervous system drug period.)

When asked which mechanisms drug companies might be targeting Younger suggested two major themes: neuroinflammation and metabolism. Right now they’re in the information gathering and small pilot study phase. That’s obviously no guarantee that a drug will be developed, but it’s a big step forward for a disease that has never, except for Hemispherx Biopharma, received any pharmaceutical company interest.

Because any new drug has to go through animal and then human trials, a new drug for ME/CFS is years away. A quicker route companies are exploring, Younger said, is drug repurposing: using drugs that are FDA approved for other conditions than ME/CFS.

In its Biovista repurposing project, The Solve ME/CFS Initiative (then the CFIDS Association of America) uncovered a low dose naltrexone / Trazodone drug combination that might work. That idea never got off the ground, but both Ron Davis of the Open Medicine Foundation and Dr. Nancy Klimas of the Institute for Neuro-Immune Studies at Nova Southeastern University believe drug repurposing has to come first, and both are pursuing it.

Low Dose Naltrexone Drug Combination Proposed for Chronic Fatigue Syndrome (ME/CFS) 
Davis has samples of every known FDA approved drug in his tool kit. If he can determine which pathways are broken he can start doing preliminary lab studies to determine which drugs might work.

The movement forward validates what advocates have been saying for years: that the first drug approved for ME/CFS is going to reset the table, and that a strong research foundation is needed to produce that drug. Pharmaceutical companies, after all, target biological abnormalities and that requires biological research. In the absence of that “in” provided by biological research, treatment studies in ME/CFS will be dominated by approaches that require no biological foundation – such as CBT.

If Ron Davis can target common pathways he can starting testing drugs in his lab
Of course, we don’t have that strong research foundation yet, but it appears that we have enough of it that pharmaceutical companies are beginning to show interest.

The NIH, hopefully, is either tuned into some of these developments or is listening, because if Younger is right, this field could be on the cusp of an important breakthrough. A timely influx of funds could do wonders.

It wasn’t just drug companies. Younger also reported a new found interest from research labs. (Later, he talked about two clinical researchers who have asked to join his lab).

Read more about treatment studies

Posted in News | Tagged , , | Comments Off on A race to produce the first drug for CFS? Dr Jarred Younger talks

NHS Continuing heathcare – deadline approaching for claiming costs

Welsh Government News post, 29 September 2016: Deadline approaching for people to claim for their care

People who believe their care should have been funded by the NHS, are being encouraged by the Welsh Government to register their intent to make a claim.

Continuing NHS Healthcare is a package of care provided free-of-charge by the NHS for those people with complex and primarily health-based needs. This can be provided in a care home or an individual’s own home.

People who think they, or someone they care for, may have been eligible for Continuing NHS Healthcare but paid for all, or part, of their care can submit a claim.

Potential claimants have until October 31st to register their intent to make a claim for continuing healthcare costs which were incurred between 1 October 2014 and 30 October 2015.

The NHS will provide advice to claimants and will complete all of the work required to review their case free of charge. This is not a legal process and there is no requirement for people to appoint a solicitor. However, if a solicitor is used, these costs cannot be reimbursed.

All claims will be reviewed within 6 months of the NHS having all the information that it needs. A publicity campaign to promote the cut-off date, together with information about where people can get further advice is also being launched.

Minister for Social Services and Public Health, Rebecca Evans, said:

“People with an illness or disability can sometimes need long-term care to help them, and their families, manage. Some people will have paid for that care themselves, when it should have been provided free by the NHS.

“If people, or their families, believe they meet the criteria for having their care paid for through Continuing NHS Healthcare, but they paid for the care themselves, I encourage them to come forward to make a claim.

“Health boards will provide free advice to anybody looking to make a claim and will also complete the necessary paper work on their behalf.”

Posted in News | Tagged , | Comments Off on NHS Continuing heathcare – deadline approaching for claiming costs

MEGA ‘big data’ study Q&A

Change.org petition update: MEGA Questions and Answers, by M.E./CFS Epidemiology and Genomics Alliance (MEGA), 5 October 2016

mega-image

Many of you have asked us questions about MEGA. We have not yet applied for funding and the patient advisory groups have not yet met to provide advice. So these are our preliminary thoughts at the moment. Some of this will change as we work on the first application (see below) and during consultations prior to future applications. We want to engage with as many people as possible especially in the current planning phase.

Has the study been funded yet?

No. We are planning to apply for funding in 2017 for the first stage of the study, setting up the world’s largest Bioresource of data and samples from CFS/ME patients. Our aim is to create a resource that all researchers all over the world can use. We will then apply for further funding for the subsequent omics-based stages of our study – searching for the biological basis to ME/CFS – once the Bioresource is set up.

Will the data be open access?

Yes. Subject to individuals’ consent, the data and the samples will be available for researchers to use. We want to rapidly increase effective research (by us, by anyone) to understand the biology, causes and different types of CFS/ME.

What case definition will you use?
To do the genetic studies that we want to do, we think we need to recruit at least 10 thousand adults and 2 thousand children. The only way to do this is to recruit patients through NHS clinics throughout England. England is the only place in the world that can collect this large number of patients in a short time frame.

Patients with CFS/ME will be identified by clinicians in the NHS clinics. The clinicians will be asked to identify patients they judge from NICE criteria to have CFS/ME. This means patients with other causes of fatigue will not be recruited including (for example): those with thyroid disease, diabetes or depression that is sufficiently severe to explain their fatigue. Patients will have been examined, a full history taken and they will have had screening blood tests (to ensure other causes of fatigue have been excluded).

We will collect sufficient information on each patient to be able to say whether they have CFS/ME using other research diagnoses (for example, the CDC [Fukuda 1994] diagnostic criteria, the IACFS criteria, Canadian criteria and so on). This is in addition to the diagnoses of CFS/ME that patients will get following NICE guidance. We will listen to our patient advisory group in terms of how much data we can collect on different diagnostic criteria. Our patients advisory groups may recommend collecting less data as patients are so ill.

Why use broad criteria?

As the symptoms and genetics of CFS/ME are highly heterogeneous we think it makes sense to build a Biobank of samples from all people diagnosed with CFS/ME (diagnosed with NICE criteria, without other causes of fatigue, as above). This is because our experience from other diseases is that the genetics found for one set of people with CFS/ME will be relevant to the genetics found for another, and even to the genetics of the population at large. But afterwards, in the computer, we will separate out various subsets of people with CFS/ME according to different diagnostic criteria. This will tell us which diagnostic criteria are more effective for which people.

Why are psychiatrists involved?

The MEGA consortium has brought together many experts from a wide range of different disciplines from across genetics, genomics, metabolomics, pain research, proteomics, psychiatry, sleep research and transcriptomics. Psychiatry needs to be there to complete the big picture yet it is just one minor aspect. MEGA will always be a Big Data ‘omics study, and will never be a psychiatric study.

What data will you collect?

We will collect symptom data on all patients to allow us to identify which patients will be identified as having CFS/ME using different diagnoses. We will also include data on fatigue, disability, anxiety and depression. We would like to collect detailed data on pain. How much data we collect will depend on what our patient advisory group says will be acceptable to consenting patients and how much funding we get.

Will you be doing additional tests?

We would like to do additional, more time-consuming and expensive tests on a sample of patients that will help us more finely phenotype (describe CFS/ME more carefully) those recruited into the study. We don’t think we will have the money to do this for everybody or for everything. We would like to do additional studies to collect more data on pain, exercise-induced stress and sleep studies and possibly some imaging. We also want to be as sure as we can that we have carefully excluded other diagnoses such as depression and anxiety as a cause of fatigue. We haven’t worked on the details for this but will be asking our patient advisory group about what they think would be feasible and acceptable given the funding limits.

What samples will you be taking?

We will take blood and urine samples that allow us to look at the genetics, the epigenetics (how genes are modified chemically), transcriptomics (identifying which genes are turned on and which are turned off), proteomics (the proteins in the blood), and the metabolomics (what small molecules are made by our enzymes and other proteins). We will use standard procedures for collection of these samples developed previously for many other studies.

Please explain why different members are part of the MEGA team?

We will upload a list of biographies and what members have to contribute in the next few days.

Sign the petition to support this study

Posted in News | Tagged , | Comments Off on MEGA ‘big data’ study Q&A